Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you use Razor Genomics RiskReveal molecular testing results to guide making recommendations for surgical adjuvant chemotherapy for Stage IA,IB & II non-squamous NSCLCA ?
Related Questions
What factors do you use when selecting which NGS platform to use for sequencing solid tumors?
Would you consider using IO alone for lung cancer patients who are PDL1 <1 but have high TMB?
What is the preferred concurrent chemotherapy regimen for limited stage small cell lung cancer with severe reaction to etoposide?
Would you consider switching capmatinib to tepotinib or vice versa due to grade 3 hepatotoxicity in a patient with metastatic NSCLC with MET Exon 14 skipping mutation?
Would you consider stopping EGFR inhibitor in EGFR mutant NSCLC on a patient who was NED for >5 years?
What treatment would you recommend for a patient with non-mutated Stage III lung squamous cell carcinoma with relapse following neoadjuvant chemoimmunotherapy, surgery, and during adjuvant immunotherapy?
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
How would you treat a patient with progressive ALK (+) NSCLC that has MET Exon 14 deletion upon repeat molecular testing on metastatic site?
Would you offer adjuvant pembrolizumab to a stage II-III adenocarcinoma of the lung who had a complete pathologic response to 4 cycles of cisplatin/pemetrexed/pembro (KN-671)?
Is there a role for surgical debulking for patients with stage IV lung sarcomatoid carcinoma?
